• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Whitefield Radiology - Mobile 29-Aug-02

Department of Health and Human ServicesDepartment of Health and Human Services            Public Health Service


Food and, Drug Administration
19900 MacArthur Blvd., Se 300
Irvine, California 92612-2445
Telephone (949) 796-7600

W/L Number: 41- 02
Inspection ID: 1970790009
WARNING LETTER
CFN: 20-30,283
FEI: 1000519375
August 29, 2002

Eileen Ruiz
Radiology Supervisor
Whitefield Radiology - Mobile
1818 North Orange Grove Avenue; Suite #102
Pomona, CA 91767-3028

Dear Ms. Ruiz:

We are writing to you because on July 30, 2002, your facility was inspected by a representative of the State of California acting on behalf of the U. S. Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under the Mammography Quality Standards Act of 1992 (MQSA), 42 U.S.C. 263b, and the Quality Standards for Mammography set forth in Tile 21, Code of Federal Regulations (C.F.R), Part 900, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following violations at your facility:

  • Level 1; Phantom quality control (QC) records were missing for at least 4 weeks for Unit #1 (a [redacted] machine, model [redacted] serial number [redacted]) which a violation of 21 C.F.R 900.12(e)(2).
  • Level 1: Phantom QC records were missing for at least 4 weeks for unit #4 (a [redacted] machine, model [redacted] serial number [redacted]) which is located in Mobile Unit #3. This is a violation of 21 C.F.R 900.12(e)(2).
  • Level 2: A performance verification test was not conducted after each move for mobile unit#1 (a [redacted] machine, model [redacted], serial number [redacted]) which is located Mobile Unit #1. This is a violation of 21 C.F.R 900.12(e)(7).

The specific problems noted above appeared on your MQSA Facility Inspection Report which was issued to your facility at the close of the inspection. Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA imposing statutory sanctions. These sanctions include, but are not limited to, placing your facility under a Directed Plan of Correction DPC), and/or charging your facility for the cost of on-site monitoring. Failure to correct these violations promptly could also cause FDA to seek civil money penalties of up to $10,000 for each failure to substantially comply with or each day of failure to substantially comply with MQSA Standards, suspension or revocation of your facility?s FDA certificate, or a court injunction against performing further mammography (see 42 U.S.C. 263b(h) through (j) of the MQSA).

It is necessary for you to act on this matter immediately. Please explain to this office, in writing, within fifteen (15) working days from the date you received this letter - the specific steps you have taken to correct all of the violations noted in this letter;

- each step your facility is taking to prevent the recurrence of similar violations;

- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and

- please provide sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to:
Thomas L. Sawyer
Director, Compliance Branch
U.S. Food & Drug Administration
19900 MacArthur Blvd., Suite #300
Irvine, CA 92612-2445
phone: (949) 798-7600


Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (telephone number: 1-800-838-7715) or through the Internet at http://www.fda.gov.

If you have more specific questions about mammography facility requirements or about the content of this letter, please feel free to contact Scott Goff (the Compliance Officer assigned to this case) at telephone number 949-798-7644.

Sincerely,

/s/

Mark Tucker for Alonza E. Cruse

District Director